🧠 Food for thought

Implications, context, and why it matters.

Korea bio big data spend trails US

• South Korea allocates $33.3 million for bio big data in 2024, which is 22% of US $148 million, per the Korea Research Institute of Bioscience and Biotechnology (KRIBB). The gap could slow precision medicine.
• First phase of the national biobank project runs through 2028 with a 6.065 trillion won (KRW) budget 1. Funding covers biobanks (repositories for biological samples, data) and recruitment. Operations need steady investment to preserve value 2.
• Bio big data stays useful only with curation, quality management, and stakeholder engagement 2. Korea may need to extend or reshape funding past the 2032 target for long-term utility.

Vendors can prep for 2026 access

• The Korea Biobank Network is a national consortium that coordinates biobanks. It already uses a common data model mapped to Systematized Nomenclature of Medicine—Clinical Terms (SNOMED CT), Logical Observation Identifiers Names and Codes (LOINC), plus the Anatomical Therapeutic Chemical (ATC) classification 3. Plans include Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) conversion and Fast Healthcare Interoperability Resources (FHIR) 3. This creates work for data standardization vendors.
• Access starts in 2026 for universities, hospitals, and research institutions 4, giving vendors time to partner with 38 medical institutions.
• Today the biobank platform limits access to each institution 3. Governance for wider researcher use is underway, with proposals for tiered openness (graduated access levels) and a single Institutional Review Board (IRB) 1. That opens space for secure analytics platforms, tiered access management, and IRB workflow automation.